First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours-Reference-Cited by-同舟云学术

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours

Published:2021-12-13 Issue: Volume: Page:
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Robbrecht Debbie^ORCID,Jungels Christiane,Sorensen Morten Mau^ORCID,Spanggaard Iben,Eskens Ferry,Fretland Signe Ø,Guren Tormod Kyrre^ORCID,Aftimos Philippe,Liberg David,Svedman Christer,Thorsson Lars,Steeghs Neeltje,Awada Ahmad

Funder

Cantargia

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-021-01657-7.pdf

Reference48 articles.

1. Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, et al. A guiding map for inflammation. Nat Immunol. 2017;18:826–31.

2. Millares L, Barreiro E, Cortes R, Martinez-Romero A, Balcells C, Cascante M, et al. Grupo Colaborativo en Cáncer de Pulmón CIBERES- CIBERONC- SEPAR—Plataforma Biobanco Pulmonar. Tumor-associated metabolic and inflammatory responses in early stage non-small cell lung cancer: local patterns and prognostic significance. Lung Cancer. 2018;122:124–30.

3. Wang L, Zhang LF, Wu J, Xu SJ, Xu YY, Li D, et al. IL-1ß-mediated repression of microRNA-101 is crucial for inflammation-promoted lung tumorigenesis. Cancer Res. 2014;74:4720–30.